SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mahieux, R. Articles by Nicot, C. Search for Related Content PubMed PubMed Citation Articles by Mahieux, R. Articles by Nicot, C. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 December 2001, Vol. 98, No. 13, pp. 3762-3769 NEOPLASIA Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage Renaud Mahieux, Cynthia Pise-Masison, Antoine Gessain, John. N. Brady, René Olivier, Emmanuelle Perret, Tom Misteli, and Christophe Nicot From Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes and Unité d'Oncologie Virale, Institut Pasteur; and the Virus Tumor Biology Section and the Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Treatment of patients with adult T-cell leukemia-lymphoma (ATLL) using conventional chemotherapy has limited benefit because human T-cell leukemia virus type 1 (HTLV-1) cells are resistant to most apoptosis-inducing agents. The recent report that arsenic trioxide induces apoptosis in HTLV-1-transformed cells prompted investigation of the mechanism of action of this drug in HTLV-1 and HTLV-2 interleukin-2-independent T cells and in HTLV-1-immortalized cells or in ex vivo ATLL samples. Fluorescence-activated cell sorter analysis, fluorescence microscopy, and measures of mitochondrial membrane potential (m) demonstrated that arsenic trioxide alone was sufficient to induce programmed cell death in all HTLV-1 and -2 cells tested and in ATLL patient samples. IB- phosphorylation strongly decreased, and NF-B translocation to the nucleus was abrogated. Expression of the antiapoptotic protein Bcl-XL, whose promoter is NF-B dependent, was down-regulated. The collapse of m and the release of cytochrome c to the cytosol resulted in the activation of caspase-3, as demonstrated by the cleavage of PARP. A specific caspase-3 inhibitor (Ac-DEVD-CHO) could reverse this phenotype. The antiapoptotic factor Bcl-2 was then cleaved, converting it to a Bax-like death effector. These results demonstrated that arsenic trioxide induces apoptosis in HTLV-1- and -2-infected cells through activation of the caspase pathway. (Blood. 2001;98:3762-3769) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia-lymphoma (ATLL).1 Treatment of patients with ATLL using conventional chemotherapy has limited benefit given that HTLV-1 cells are resistant to most apoptosis-inducing agents.2,3 This may in part be because HTLV-1 leukemic cells overexpress the multidrug resistance protein and the lung-resistance protein, resulting in the pumping of a wide spectrum of agents from the plasma membrane and preventing them from entering the cytoplasm.4,5 In addition, the down-regulation of Fas-ligand expression and rare cases of mutations in the Fas gene sequence have been reported and could also impair the induction of apoptosis through this pathway.6 In vivo, but not in vitro, the combination of zidovudine (AZT) with interferon- is a partially effective treatment that induces cell death in HTLV-1-infected cells.7,8 In vitro, retinoic acid9,10 or arsenic trioxide (As2O3), in combination with IFN-, can also induce cell death in HTLV-1-transformed cells11,12 through mechanisms that remain unclear but that may involve the down-regulation of NF-B in the latter case.13 Programmed cell death, or apoptosis, consists of a highly regulated series of events allowing the organism to control cell number and tissue size.14 It occurs in 3 phasesinitiation, commitment to cell death, and execution. During apoptosis, a complex set of proteins is activated. Among them, caspases play a key role and act as initiators (for review, see 15). These cysteine proteases are normally present as pro-enzymes and are proteolytically cleaved to active heterodimers. They have an active-site cysteine and mediate apoptosis by proteolysis of specific substrates. Substrate specificity is determined by the 4-residue amino-terminal to the cleavage site. Caspase-dependent cleavage can either activate or inactivate the target protein. Close to 100 caspase substrates have been reported.16 Poly (ADP-ribose) polymerase (PARP), a regulator of DNA repair, and Bcl-2 are known substrates of caspase-3. Mitochondria have been recently recognized to play a major role in the control of apoptosis or programmed cell death.14,17 Members of the Bcl-2 family that interact with the permeability transition pore complex regulate permeabilization of mitochondrial membranes, a decisive feature of early cell death. Bcl-2 is a member of an expanding family of related proteins. Some of them are proapoptotic (Bax, Bak, Bid, Bcl-XS) and some are antiapoptotic (Bcl-2, Bcl-XL) (for review, see 14,18). It has been shown that the presence of Bcl-2 blocked the activation of caspase-3. Howeverand adding another level of complexityBcl-2, which inhibits cell death, can also be converted to a Bax-like death effector through its cleavage at Asp-34 by caspase-3.19,20 Interestingly, Bcl-2 and Bcl-XL are overexpressed in HTLV-1 cells.21,22 In the latter case, this phenomenon is linked with the constitutive activation of the NF-B pathway by Tax.23 Tax is a 42-kd protein whose expression is sufficient to induce murine cell transformation or human T cell immortalization.24-26 Tax has pleiotropic effects: not only does Tax transactivate the viral promoter, it is also able to activate or repress the expression or functions of a wide array of genes.27,28 Many of them are regulators of the cell cycle (p21, p53, MAD-1, p16INKA) or of apoptosis (Bcl-2, Bcl-XL, and caspases).2,21,22,28-35 Tax is also competent for inhibiting DNA repair through the suppression of the nucleotide-excision repair and the base excision pathways.36,37 The pro- or antiapoptotic role of Tax is still a matter of debate. Recent data suggest a proapoptotic function for this protein,38 even though it inhibits the caspase cascade.31 Tax-expressing cells have a striking featureconstitutive NF-B activation.23 This promotes the expression of antiapoptotic factors21 and tumor formation in transgenic mice.39 Interestingly, arsenic treatment inhibits NF-B activation in different non-HTLV cell lines through interactions with the I subunit of the I complex.40,41 Because NF-B activation has been strongly linked to Tax-induced immortalization, we investigated whether the expression or the function of several apoptosis-regulating proteins, whose expression or function is regulated through the NF-B pathway, was modified by arsenic trioxide-IFN- treatment in HTLV-1- and -2-infected cells. In this report, we demonstrate that arsenic trioxide treatment induced apoptosis in all HTLV-1 and -2 cell lines tested, whether they were interleukin-2 (IL-2) dependent or independent, and in cells obtained from patients with HTLV-1 ATLL. Drug treatment induced the disruption of the mitochondrial m and the reversion of NF-B activation. Apoptosis was correlated with caspase-3 activation and caspase-3-dependent cleavage of PARP and of Bcl-2. Cleavage of Bcl-2 promoted the release of cytochrome c from the mitochondria. Addition of a specific caspase-3 inhibitor prevented arsenic trioxide-induced apoptosis. Finally, Bcl-XL protein, whose promoter is NF-B dependent, was also down-regulated. These results demonstrated that though multiple apoptosis pathways are inhibited in HTLV-1- and -2-infected cells, these effects were reversible. This may open new avenues for treating patients with HTLV ATLL.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Drugs IFN- (Roche Molecular Biochemicals, Basel, Switzerland) or arsenic trioxide (Sigma, l'Isle d'Abeau, France) was used at 100 units/mL and 1 µM, respectively, as previously described.11 The cell-permeable reversible caspase-3 inhibitor Ac-DEVD-CHO (Bachem, Voisins-le-Bretonneux, France) was dissolved in dimethyl sulfoxide (Sigma) and was used at 50 µM and 100 µM. Cell lines and ATLL patient cells HUT-102, MT-2, C8166, and C91/PL are HTLV-1-transformed cell lines, and C19 is an HTLV-2-transformed cell line. CEM, MOLT-4, and Jurkat are leukemic cells not infected by HTLV viruses. All these cells lines were grown in Roswell Park Memorial Institute medium (RPMI-1640; Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum, L-Gln, and penicillin-streptomycin. Boul and Bes (HTLV-1 IL-2-dependent cell lines isolated from a patient with TSP/HAM and a patient with ATLL, respectively)33 and PH878 and PH868 (short-term cultured cells from 2 patients with ATLL) were grown in the same medium supplemented with 20% fetal calf serum and 10% recombinant IL-2 (Roche Molecular Biochemicals). PH868 is a patient with chronic ATLL (WBC showed 2.6 × 109 lymphocytes/L), and PH878 is a patient with acute ATLL (WBC showed 10.7 × 109 lymphocytes/L). FACS analysis and 4',6'-diamidino-2-phenylindole dihydrochloride staining After 48 to 72 hours of treatment, cells were harvested and washed in phosphate-buffered saline (PBS) without Ca++/Mg2+ (Life Technologies). They were then stained using the Vybrant Apoptosis kit (Molecular Probes, Eugene, OR). Briefly, annexin V conjugated to fluorescein allowed the identification of apoptotic cells, whereas propidium iodide (PI) allowed the identification of dead cells. Apoptotic cells were annexin V positive and PI negative. For 4',6'-diamidino-2-phenylindole dihydrochloride (DAPI) staining experiments, the chambers were coated with poly-L-lysine overnight. Cells were then added to the slide, fixed with 7% paraformaldehyde, washed in PBS without Ca++/Mg2+, and incubated with DAPI (4'-6'-diamine-2 phenylindole dihydrochloride) (Sigma) at 0.1 µg/mL. Cells were then mounted using Vectashield (Vector Laboratories, Burlingame, CA). Mitochondrial membrane potential (m) changes To investigate the changes in mitochondrial membrane potential that occur during apoptosis, the Apoalert Mitochondrial Membrane Sensor kit (Clontech, Palo Alto, CA) was used. Briefly, after 48 to 72 hours of treatment, cells incubated with Mitosensor reagent for 20 minutes at 37°C. After centrifugation, they were resuspended in incubation buffer and analyzed by fluorescence-activated cell sorter scanner (FACS). Mitochondria containing Mitosensor (normal mitochondria) aggregates were detectable in the PI channel, and Mitosensor monomers (mitochondria with altered membrane permeability) were detectable in the fluorescein isothiocyanate channel. Cell proliferation and viability assay To measure cellular proliferation or viability, a cell proliferation-viability kit (XTT; Roche Molecular Biochemicals) was used. In this assay, tetrazolium salt XTT is cleaved to form an orange formazan dye by metabolic active cells. This dye is directly quantified using an enzyme-linked immunosorbent assay reader at 492 nm. Whole-cell extracts and Western blot analysis Cells were lysed in TNN buffer (50 mM Tris HCl, pH 7.4, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM dithiothreitol) in the presence of protease inhibitors (Complete, Boehringer Mannheim, Germany) for 20 minutes on ice. The lysate was then centrifuged for 10 minutes at 4°C, and the supernatant was frozen at 80°C. Protein concentration was determined by the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Tris-glycine gels (Novex, Groningen, Netherlands)at 4% to 20%, 10%, or 16%were used as recommended by the manufacturer. After transfer to an Immobilon polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA), detection was performed with an enhanced chemiluminescence system (Supersignal West Dura; Pierce, Rockford, IL) as previously described.42 Electrophoretic mobility shift assay Nuclear and cytoplasmic extracts were made as previously described. The 8 mC/EBP oligonucleotide was used as an NF-B-specific probe, as previously described.43 Mitochondria purification Cells were washed in PBS without Ca++/Mg2+, the pellet was resuspended in lysis buffer (0.15 mM MgCl2, 10 mM KCl, 10 mM Tris-HCl, pH 7.6, and proteases inhibitors) and kept for 30 minutes on ice. Membranes were then disrupted with a dounce homogenizer, and RLM buffer was added (0.2 mM saccharose, 10 mM Tris-HCl, pH 7.4, ethylene glycol tetraacetic acid (EGTA)-Tris 0.1 mM final). Lysates were centrifuged for 3 minutes, at 900g at 4°C. Supernatants were then centrifuged at 7000g for 10 minutes at 4°C. Pellets were resuspended in RLM buffer and centrifuged again at 7000g for 10 minutes at 4°C. Finally, the pellet was resuspended in protein extraction buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate) containing proteases inhibitors. Lysates were cleared by centrifugation in a microcentrifuge at 14 000 rpm for 15 minutes and were used for Western blot analysis, as described above. Antibodies Anti-Bcl-2 (sc-509), Bcl-2 C21 (sc-783), Bax (sc-526), anti-caspase-3 (sc-7148), phospho-IB- (sc-8404), and -tubulin (sc-9104) were purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-cytochrome c (65971A) and anti-PARP (65196E) were purchased from PharMingen (San Diego, CA). Anti Bcl-XL/XS (06-851) was purchased from Upstate Biotechnology (Lake Placid, NY), and anti p53 DO-1 (Ab-6) was purchased from Oncogene Research (Cambridge, MA). Anti-Tax Tab172 was previously described.44 Anti-gag p24 (9281) was purchased from Cambridge Biotech (Rockville, MD). Anti-rabbit and anti-mouse immunoglobulin G horseradish peroxidase-conjugated antibodies were purchased from Amersham (Amersham Pharmacia, Saclay, France) and were used as recommended by the manufacturer. Confocal microscopy Cells were centrifuged (Shandon, Pittsburgh, PA) on Superfrost/Plus glass slides (Menzel-Glaser, Braunschweig, Germany) and fixed with 4% paraformaldehyde. They were then permeabilized (PBS/0.1% Triton), blocked (2% PBS-bovine serum albumin [BSA]), and incubated with anti-cytochrome c antibody (65971A) (PharMingen) for 1 hour at room temperature. Cells were washed in PBS/2% BSA and incubated with anti-rabbit-fluorescein isothiocyanate-conjugated antibodies (Uptima, Montluçon, France) for 1 hour at room temperature. The coverglass was finally washed, mounted with Vectashield (Vector Laboratories), and examined using laser confocal microscope argon-krypton (Leica).     Results Top Abstract Introduction Materials and methods Results Discussion References Arsenic trioxide alone or in combination with IFN- induces apoptosis of HTLV-1- and HTLV-2-immortalized or -transformed cells Arsenic trioxide (As2O3) and IFN- were recently demonstrated to induce apoptosis in 2 HTLV-1-transformed cells.11 To investigate the mechanism of action of arsenic trioxide, associated or not associated with IFN-, we treated with these chemicals a series of HTLV-1-immortalized (IL-2-dependent) cells (Bes, Boul), HTLV-1-transformed (IL-2-independent) cells (C8166, HUT-102, MT-2), HTLV-2-transformed (C19) cells, or noninfected control cells (Jurkat and MOLT-4). After 60-hour treatment, the cells were analyzed by FACS using double staining (DAPI/annexin V). Apoptotic cells were scored as annexin V+/PI versus dead cells, which were PI+. Figure 1A shows a typical FACS result obtained with MT-2 cells. An apoptotic population was detected when As2O3 was added to the cell culture. Similar FACS results were obtained with C8166 HTLV-1-infected cells (data not shown). Control Jurkat and MOLT-4 cells were not affected by As2O3 treatment (data not shown and Figure 2). DAPI staining of MT-2 cells (Figure 1B) demonstrated the expected nuclear condensation after arsenic trioxide or arsenic trioxide-IFN- treatment, whereas control treatment or IFN- alone had no or little effect. View larger version (20K): [in this window] [in a new window]   Figure 1. As2O3 or IFN- + As2O3 induced apoptosis in HTLV-1 infected cell lines. (A) FACS, (B) DAPI staining, or (C) m collapse analyses of HTLV-1-infected cells after various treatments. (A) MT-2 cells were treated with buffer control, IFN-, As2O3, or IFN- + As2O3 for 60 hours. Cells were then harvested and washed in PBS without Ca++/Mg2+. They were stained using the Vybrant Apoptosis kit. Annexin V conjugated to fluorescein allowed the identification of apoptotic cells, whereas PI allowed the identification of dead cells. Apoptotic cells were annexin V+ and PI. (B) DAPI staining of MT-2 cells after the same treatments. Magnification × 40. (C) m Collapse was measured with the Apoalert Mitochondrial Membrane Sensor kit. Results are representative of at least 2 experiments performed with different HTLV-1-transformed cells. View larger version (20K): [in this window] [in a new window]   Figure 2. HTLV-1- and HTLV-2-transformed cell lines as well as HTLV-1 cells from patients are sensitive to As2O3. (A) HTLV-1- or HTLV-2-transformed cells (C8166, HUT-102, C19), (B) HTLV-1 IL-2-dependent cells lines from TSP/HAM or ATL patients (Boul, Bes), (C) ATL cells from patients (PH868 and PH878), and (D) non-HTLV control cell lines (CEM, MOLT-4, T2) were treated with buffer control, IFN-, As2O3 or IFN- + As2O3 for 60 hours and then processed using the XTT assay kit. Panels A, B, and D represent the mean of 3 independent experiments performed in duplicate. Panel C represents the mean of 2 independent experiments. Changes in m are a critical step in cells undergoing apoptosis, regardless of the death signal. Therefore, m was also measured in MT-2 cells (Figure 1C). Arsenic trioxide or As2O3+ IFN--treated cells that entered apoptosis showed an altered mitochondrial membrane permeability that led to m collapse. By contrast, MT-2 cells treated with buffer control or with IFN- did not show any change in m (Figure 1C; compare panels 3 and 4 with panels 1 and 2). To investigate whether all HTLV-1- or HTLV-2-infected cell lines or cells from patients were also sensitive to As2O3 with or without IFN-, we conducted a series of XTT assays that allowed us to measure cellular proliferation and viability after drug treatment (Figure 2). Confirming the FACS results, HTLV-1-immortalized (IL-2-dependent) cell lines obtained from Boul and Bes patients and HTLV-1-transformed HUT-102, C8166, C91/PL (data not shown), HTLV-2-transformed C19 or short-term cultured cells from 2 patients with ATLL (PH878 and PH868) displayed a significant reduction in cellular proliferation and viability after As2O3 or As2O3 + IFN- treatment. By contrast, control treatment or IFN- treatment had no effect (Figure 2A-C). As control cells, CEM, T2, MOLT-4, and Jurkat were tested. CEM, MOLT-4, and Jurkat proliferation was not affected by any treatment. Strikingly, however, As2O3 and As2O3 + IFN- induced viability and growth alteration in T2 (CEM-derived) cells. This suggested that As2O3 did not specifically induce apoptosis in HTLV-1- or HTLV-2-infected cells but did affect a cellular pathway that might have been altered in HTLV-1 and -2 cells and in the T2 cell line (Figure 2D). NF-B activity down-regulated after arsenic trioxide or arsenic trioxide-IFN- treatment Because arsenic was reported to inhibit NF-B activity in various cell lines,40,41 we investigated whether, as suggested by others,13 this was the case in HTLV-1 cell lines. Retardation gels using an NF-B-specific probe and IB- phospho-specific WB confirmed that As2O3, whether used alone (data not shown) or in combination with IFN-, was able to inhibit the constitutive IB- phosphorylation ordinarily present in HTLV-1 cell lines (Figure 3A; compare lanes 2 and 1). This led to a decrease in NF-B translocation to the nucleus and consequently diminished binding to an NF-B-specific probe (Figure 3C; compare lanes 2 and 3). In contrast, control treatment (Figure 3A, lane 1) or IFN- alone (data not shown) did not induce any change. Supershift experiments and competition with a cold probe demonstrated the binding specificity (data not shown). View larger version (36K): [in this window] [in a new window]   Figure 3. Inhibition of NF-B activation by As2O3 in HTLV-1-infected cells. (A) Sixty micrograms cytoplasmic protein was resolved on 10% to 20% Tris-glycine, transferred to PVDF membranes, and probed with an antibody specific for the phosphorylated form of IB. Results are representative of 2 independent experiments. (B) Comparable protein loading was verified using an antibody specific for the housekeeping gene product -tubulin. Results are representative of 2 independent experiments. (C) Electrophoretic mobility shift assay using a previously published NF-B-specific probe43 mixed with no extract (lane 1), mixed with 5 µg nuclear extract obtained from MT-2 treated with control buffer (lane 2), or treated with As2O3 + IFN- and run on a 6% DNA retardation gel (lane 3). Specificity of the NF-B binding was checked by competition with a 50-fold excess of cold probe (data not shown). Switch from Bcl-XL to Bcl-XS after As2O3 + IFN- treatment NF-B factors affect the transcription of some Bcl-2 family members such as Bcl-XL.21,22 They also alter p53 transcriptional activity.44,45 Moreover, p53 drives Bax expression. Because we showed that As2O3 affected NF-B activity, the level of expression of Bax, Bcl-XL, Bcl-XS, and p53 was investigated after drug treatment using whole-cell extracts from C8166 (Figure 4A-C) or from MT-2 and HUT-102 (data not shown). Overall levels of Bax (Figure 4A) and p53 (Figure 4C) remained unchanged, even after the addition of As2O3 + IFN-. Similar results were obtained for p21 (data not shown). Alternative splicing of the Bcl-X gene gives rise to 2 proteins with antagonistic functions: Bcl-XL (antiapoptotic) or Bcl-XS (proapoptotic).46 HTLV-1-infected cells display high levels of Bcl-XL.22 Strikingly, we noted a strong decrease in Bcl-XL expression after As2O3 or As2O3 + IFN- treatment (Figure 4B). Of note, increased expression of the alternatively spliced, proapoptotic protein Bcl-XS was seen in all the IFN--treated C8166 samples. Such an increase in Bcl-XS expression was not observed in the other HTLV-1-cell lines tested, suggesting that this is not a common phenomenon in HTLV-1 cells treated with IFN- (data not shown). The altered expression levels of Bcl family members might, therefore, have been a factor that influenced the shift toward apoptosis in C8166 cells. -Tubulin Western blot (Figure 4D) confirmed equal loading of protein extracts. View larger version (18K): [in this window] [in a new window]   Figure 4. BclXL/XS expression, but not Bax or p53 expression, is modified by As2O3 in HTLV-1-transformed and -immortalized cell lines. Sixty micrograms total protein from C8166 cells was resolved on 10% to 20% Tris-glycine, transferred to PVDF membranes, and probed with specific antibodies for (A) Bax, (B) Bcl-XL/XS, (C) and p53. Results are representative of at least 2 independent experiments using different HTLV-1-infected cells. Comparable protein loading was verified using an antibody specific for the housekeeping gene product -tubulin (D). Lane 1, control treatment; lane 2, IFN-; lane 3, As2O3; lane 4, As2O3 + IFN-. Involvement of caspase-3 in arsenic trioxide-induced apoptosis m Collapse results in the activation of caspases.17 Caspase-3 is a critical downstream protease in the caspase cascade, and PARP is one substrate of the caspase-3 protease activity associated with apoptosis. Interestingly, the activation of caspase-3 was detected after As2O3 (data not shown) or As2O3 + IFN- treatment, as demonstrated by cleavage of the pro-enzyme (Figure 5A; compare lane 2 [arsenic treated] with lane 1 [control]). This demonstrates that this cysteine protease was activated by the addition of As2O3. We then looked for potential PARP cleavage in As2O3-treated MT-2 cells. Indeed, the 85-kd fragment representing the cleaved form of PARP was detected after treatment of MT-2 HTLV-1 cells by As2O3 alone or in combination with IFN- (Figure 5B; compare lanes 3 and 4 with lanes 1 and 2). This demonstrates the involvement of caspase-3 in this process. View larger version (25K): [in this window] [in a new window]   Figure 5. As2O3 induces caspase-3 activation and Bcl-2 cleavage. Sixty micrograms total proteins from MT-2 cells were resolved on 4% to 20% Tris-glycine gels transferred to PVDF membranes and probed with specific antibodies for (A) caspase-3 and (B) PARP. Comparable protein loading was verified using an antibody specific for the housekeeping gene product -tubulin (data not shown). (C) Sixty micrograms mitochondrial-enriched fraction proteins from MT-2 or HUT-102 cells was resolved on 4% to 20% Tris-glycine transferred to PVDF membranes and probed with specific antibodies for Bcl-2. (A-C) Results are representative of at least 2 independent experiments using different HTLV-1-infected cells (B-C, panel 1). Lane 1, control treatment; lane 2, IFN-; lane 3, As2O3; lane 4, As2O3 + IFN-. (A, C, panels 2 and 3) Lane 1, control treatment; lane 2, As2O3 + IFN-. Because Bcl-2 is also cleaved by caspase-3 and results in a proapoptotic form,20 we performed MT-2 and HUT-102 subcellular fractionation and mitochondrial enrichment and then Western blot analysis to search for such Bcl-2 posttranslational modification. The proapoptotic, 23-kd Bcl-2 form was detected in As2O3-treated MT-2 cells (Figure 5C; compare lanes 3 and 4 with lanes 1 and 2 in panel 1 and lane 2 with lane 1 in panel 2) and in HUT-102 cells (Figure 5C; compare lane 2 [arsenic trioxide + IFN-] with lane 1 [control] in panel 3). This confirmed that As2O3-induced apoptosis in HTLV-infected cells was caspase-3 dependent. Ultimately, HUT-102 cells were also treated with Ac-DEVD-CHO, a specific caspase-3 inhibitor,47 in the presence of As2O3 + IFN-. As seen on Figure 6, incubating HTLV-1-infected cells with DEVD-CHO during As2O3 treatment completely prevented death. Ac-DEVD-CHO treatment of HUT-102 in the absence of As2O3 had no effect on cell growth (data not shown). This result clearly demonstrated the role of the caspase-3 in As2O3-induced apoptosis. View larger version (12K): [in this window] [in a new window]   Figure 6. Ac-DEVD-CHO, a caspase-3-specific inhibitor, can prevent As2O3-induced apoptosis. HUT-102 cells were preincubated with Ac-DEVD-CHO at 100 µM, for 2 hours, then treated with control buffer or with As2O3 + IFN- for 60 hours in the presence of Ac-DEVD-CHO. XTT assay was then performed, as described in "Materials and methods." Graph represents the mean of 2 separate experiments performed in triplicate. Lane 1, control treatment; lane 2, As2O3 + IFN-; lane 3, As2O3 + IFN- + Ac-DEVD-CHO. Caspase-3-dependent cleavage of Bcl-2 promotes cytochrome c release Bcl-2 cleavage induced the release of cytochrome c from the mitochondria to the cytosol in baby hamster kidney cells.20 We performed a series of confocal microscopy experiments to look for cytochrome c release. Staining of cytochrome c was punctuate and in a mitochondrial distribution around a well-defined nucleus in cells treated with buffer control (Figure 7A) or with IFN- (data not shown). By contrast, after As2O3 treatment, cytochrome c staining was no longer clearly defined. (Figure 7B). View larger version (78K): [in this window] [in a new window]   Figure 7. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c from the mitochondria. HUT-102 cells were treated with (A) control buffer, IFN- (data not shown), As2O3 (data not shown), or (B) with As2O3 + IFN- for 60 hours. They were stained with a specific cytochrome c antibody and were analyzed by confocal microscopy. Magnification × 63.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Programmed cell death, or apoptosis, is a genetic program that allows the control of cellular homeostasis. Disruption of apoptosis can contribute to a number of diseases, including cancer.48 It is now well established that anticancer agents induce apoptosis and that disruption of apoptotic programs can reduce treatment sensitivity.49 In vitro and in vivo HTLV-1 cells are resistant to most apoptosis-inducing agents2,3; this might, in part, be because HTLV-1 cells overexpress PgP.4 Inorganic arsenic trioxide (As2O3) was recently reported to induce complete remission in a high proportion of patients with acute promyelocytic leukemia (APL).50,51 In the APL cell line NB4, apoptosis might involve the down-regulation of Bcl-2 expression and the modulation of PML-RAR expression or localization.52-54 However, in other APL cells, the involvement of PML-RAR is a matter of controversy.55 Because HTLV-1 causes ATLL, investigators have been prompted to determine whether this chemical is also active in vitro on cell lines infected with HTLV-1.11,12 Indeed, As2O3 in combination with IFN- kills HTLV-1-transformed cells possibly through Tax down-regulation, leading to NF-B repression.11,13,23 Caspase cascade is inhibited in HTLV-1-infected cells.31 Here we demonstrate that this inhibition is reversible and participates in arsenic-induced programmed cell death. We show that concomitant with NF-B inactivation, caspase cascade is reactivated, leading to PARP and to Bcl-2 cleavage and to the release of cytochrome c. Finally, the reversion of As2O3 effects can be achieved by a specific caspase-3 inhibitor, DEVD-CHO. These results are in disagreement with those of El-Sabban et al.13 The DEVD-CHO concentration we used (100 µM vs 50 µM used by El-Sabban et al.13) or the fact that we used DEVD-CHO instead of z-VAD might explain the differences observed. Bcl-2 cleavage by caspase-3 can also lead to apoptosis.19,20 Indeed, this was the case when HTLV-1 cells were treated with As2O3. Therefore, our results illustrate that though Bcl-2 is postulated to inhibit cell death by acting upstream of caspases, occasionally it might be one of their downstream substrates. Moreover, it has been established that apoptosis can be induced by an elevated number of proapoptotic protein heterodimers.56 Nonetheless, HTLV-1-infected cells have an enhanced ratio of antiapoptotic protein homodimers.22 The possibility that arsenic trioxide treatment modifies such a ratio is an interesting hypothesis that will be examined. Because p53 is wild type in sequence but functionally inactive in HTLV-infected cells,42,57 one intriguing possibility is that arsenic trioxide treatment causes a reactivation of p53. One might expect that because in our studies the activation of NF-B by Tax directly correlated with phosphorylation-dependent inhibition of p53 transactivation function44 and that arsenic down-regulated NF-B translocation, p53 would become functional in HTLV-1 cells by reversing phosphorylation-induced inhibition. Unfortunately, in preliminary studies, we found that arsenic trioxide treatment of control uninfected MOLT-4 cells caused a stress response and subsequent phosphorylation of p53. In fact, in recent reports,58 it is suggested that arsenic induces p53 activity. Although we did not see a change in serine 15 phosphorylation in arsenic trioxide-treated HTLV-1 cells (data not shown), we could not determine whether a shutdown of NF-B by arsenic relieved p53 transcriptional inhibition by altering p53 phosphorylation status. Detailed analysis is under way to determine the phosphorylation pattern and functionality of p53 in arsenic trioxide-treated HTLV-1 cells. We do note that in examining the level of Bax and p21WAF, 2 well-characterized p53-responsive genes, we did not see an increase in HTLV-infected cells treated with arsenic trioxide. This suggests that perhaps the apoptosis induced by arsenic trioxide, though caspase dependent, was p53 independent. In addition, we think that As2O3-induced NF-B down-regulation in HTLV-1 cells did not result from Tax down-regulation itself but rather from a direct effect of the chemical component on the I complex, as reported by other investigators in different cellular systems.40 Therefore, p53 inhibition may still be activated. In fact, conjoined with a Tax decrease, we reproducibly detected by Western blot analysis an increase in p24 gag protein expression after As2O3 treatment (Figure 8A-B). This could indicate that, after stress, there is a shift toward viral production. Indeed, such an effect has been reported in HTLV-1 cells treated with sodium arsenite59 and in HHV-8-infected primary effusion lymphoma cells treated with arsenic trioxide (G. Torelli, written communication, 2000). These results would also explain why the addition of As2O3 is effective on freshly isolated ATLL cells, which show little, if any, Tax expression but do show NF-B activity.60 This hypothesis is now under study, but it has also been raised by other investigators who treated ATLL cells with all-trans retinoic acid.61 These results also suggest that using As2O3 in vivo to treat HTLV-1- or HTLV-2-infected patients might have pernicious effects. The drug treatment would be anticipated to increase viral production and, therefore, to expand the number of newly infected cells. However, given that in vitro AZT protects cells from infection with HTLV-1, one could suggest that treatment based on the combination of As2O3 and AZT would be expected to induce cell death in HTLV-1-infected cells and prevent new infection. View larger version (24K): [in this window] [in a new window]   Figure 8. Tax expression is down-regulated but p24 is up-regulated after arsenic trioxide treatment. MT-2 cells were treated with control buffer, IFN-, As2O3, or As2O3 + IFN- for 48 hours. Sixty micrograms total protein was then resolved on 16% Tris-glycine gels transferred to PVDF membranes and probed with specific antibodies for (A) Tax or (B) Gag p24. Comparable protein loading was verified using an antibody specific for the -tubulin protein (C). In conclusion, these results confirm that although multiple apoptotic pathways are inhibited in HTLV-1-infected cells, these effects are reversible. This may open new avenues for treating HTLV-1-infected patients.     Acknowledgments We thank Luigi Ravagnan for his technical advice during mitochondria enrichment, Wilfrid Mahieux for preparation of the figures, and Nicole Israël for the generous gift of some reagents.     Footnotes Submitted June 15, 2001; accepted August 8, 2001. Supported by a grant from Association de Recherche sur le Cancer and a Bourse Roux from the Pasteur Institute (R.M.). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Renaud Mahieux, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris cedex 15, France; e-mail: rmahieux{at}pasteur.fr.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Takatsuki K, Yamaguchi K, Kawano F, et al. Clinical aspects of adult T-cell leukemia/lymphoma (ATL). Princess Takamatsu Symp. 1984;15:51-57[Medline] [Order article via Infotrieve]. 2. Cereseto A, Kislyakova T, Washington Parks R, Nicot C, Franchini G. Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I-infected T-cells. J Gen Virol. 1999;80:1575-1581[Abstract]. 3. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T cell leukemia: a review of established and new treatments. BioDrugs. 1998;10:447-462[Medline] [Order article via Infotrieve]. 4. Lau A, Nightingale S, Taylor GP, Gant TW, Cann AJ. Enhanced MDR1 gene expression in human T-cell leukemia virus-I-infected patients offers new prospects for therapy. Blood. 1998;91:2467-2474[Abstract/Free Full Text]. 5. Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells over-express the multidrug-resistance- protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer. 1999;82:599-604[CrossRef][Medline] [Order article via Infotrieve]. 6. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 1998;91:3935-3942[Abstract/Free Full Text]. 7. Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia. 2000;14:716-721[CrossRef][Medline] [Order article via Infotrieve]. 8. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751[Free Full Text]. 9. Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res. 1998;22:611-618[CrossRef][Medline] [Order article via Infotrieve]. 10. Maeda Y, Miyatake J, Sono H, et al. 13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis: possible new indication for retinoid therapy. Intern Med. 1996;35:180-184[Medline] [Order article via Infotrieve]. 11. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-283[Abstract/Free Full Text]. 12. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol. 1998;103:721-728[CrossRef][Medline] [Order article via Infotrieve]. 13. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I-transformed cells is associated with tax down-regulation and reversal of NF-B activation. Blood. 2000;96:2849-2855[Abstract/Free Full Text]. 14. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776[CrossRef][Medline] [Order article via Infotrieve]. 15. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev. 2000;64:821-846[Abstract/Free Full Text]. 16. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424[CrossRef][Medline] [Order article via Infotrieve]. 17. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp. 1999;66:1-15[Medline] [Order article via Infotrieve]. 18. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419[CrossRef][Medline] [Order article via Infotrieve]. 19. Cheng EH, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 1997;278:1966-1968[Abstract/Free Full Text]. 20. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem. 1999;274:21155-21161[Abstract/Free Full Text]. 21. Tsukahara T, Kannagi M, Ohashi T, et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-B in apoptosis-resistant T-cell transfectants with Tax. J Virol. 1999;73:7981-7987[Abstract/Free Full Text]. 22. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 2000;96:275-281[Abstract/Free Full Text]. 23. Li XH, Gaynor RB. Regulation of NF-B by the HTLV-1 Tax protein. Gene Expr. 1999;7:233-245[Medline] [Order article via Infotrieve]. 24. Rosin O, Koch C, Schmitt I, et al. A human T-cell leukemia virus Tax variant incapable of activating NF-B retains its immortalizing potential for primary T-lymphocytes. J Biol Chem. 1998;273:6698-6703[Abstract/Free Full Text]. 25. Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol. 1992;66:4570-4575[Abstract/Free Full Text]. 26. Grassmann R, Fleckenstein B, Desrosiers RC. Viral transformation of human T lymphocytes. Adv Cancer Res. 1994;63:211-244[Medline] [Order article via Infotrieve]. 27. Yoshida M. HTLV-1 Tax: regulation of gene expression and disease. Trends Microbiol. 1993;1:131-135[CrossRef][Medline] [Order article via Infotrieve]. 28. Mesnard JM, Devaux C. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology. 1999;257:277-284[CrossRef][Medline] [Order article via Infotrieve]. 29. de La Fuente C, Santiago F, Chong SY, et al. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol. 2000;74:7270-7283[Abstract/Free Full Text]. 30. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell. 1998;93:81-91[CrossRef][Medline] [Order article via Infotrieve]. 31. Kawakami A, Nakashima T, Sakai H, et al. Inhibition of caspase cascade by HTLV-I tax through induction of NF-B nuclear translocation. Blood. 1999;94:3847-3854[Abstract/Free Full Text]. 32. Pise-Masison CA, Choi KS, Radonovich M, et al. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol. 1998;72:1165-1170[Abstract/Free Full Text]. 33. Santiago F, Clark E, Chong S, et al. Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. J Virol. 1999;73:9917-9927[Abstract/Free Full Text]. 34. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607-1614[Medline] [Order article via Infotrieve]. 35. Yamato K, Oka T, Hiroi M, et al. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-I-infected cells. Jpn J Cancer Res. 1993;84:4-8[CrossRef][Medline] [Order article via Infotrieve]. 36. Philpott SM, Buehring GC. Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene. J Natl Cancer Inst. 1999;91:933-942[Abstract/Free Full Text]. 37. Lemoine FJ, Kao SY, Marriott SJ. Suppression of DNA repair by HTLV type 1 tax correlates with tax trans-activation of proliferating cell nuclear antigen gene expression. AIDS Res Hum Retroviruses. 2000;16:1623-1627[CrossRef][Medline] [Order article via Infotrieve]. 38. Nicot C, Harrod R. Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-cell lymphotropic virus type 1 Tax protein. Mol Cell Biol. 2000;20:8580-8589[Abstract/Free Full Text]. 39. Kitajima I, Shinohara T, Bilakovics J, et al. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science. 1992;258:1792-1795[Abstract/Free Full Text]. 40. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-B activation by arsenite through reaction with a critical cysteine in the activation loop of IB kinase. J Biol Chem. 2000;275:36062-36066[Abstract/Free Full Text]. 41. Roussel RR, Barchowsky A. Arsenic inhibits NF-B-mediated gene transcription by blocking IB kinase activity and IB phosphorylation and degradation. Arch Biochem Biophys. 2000;377:204-212[CrossRef][Medline] [Order article via Infotrieve]. 42. Mahieux R, Pise-Masison CA, Nicot C, et al. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses. 2000;16:1677-1681[CrossRef][Medline] [Order article via Infotrieve]. 43. Mahieux R, Lambert PF, Agbottah E, et al. Cell cycle regulation of human interleukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol. 2001;75:1736-1743[Abstract/Free Full Text]. 44. Pise-Masison CA, Mahieux R, Jiang H, et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-B pathway and is dependent on p53 phosphorylation. Mol Cell Biol. 2000;20:3377-3386[Abstract/Free Full Text]. 45. Webster GA, Perkins ND. Transcriptional cross-talk between NF-B and p53. Mol Cell Biol. 1999;19:3485-3495[Abstract/Free Full Text]. 46. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608[CrossRef][Medline] [Order article via Infotrieve]. 47. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43[CrossRef][Medline] [Order article via Infotrieve]. 48. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462[Abstract/Free Full Text]. 49. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol. 1999;187:127-137[CrossRef][Medline] [Order article via Infotrieve]. 50. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360[Abstract/Free Full Text]. 51. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345-3353[Abstract/Free Full Text]. 52. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061[Abstract/Free Full Text]. 53. Sternsdorf T, Puccetti E, Jensen K, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol. 1999;19:5170-5178[Abstract/Free Full Text]. 54. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999;91:772-778[Abstract/Free Full Text]. 55. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML- and PML-RAR-independent manner. Blood. 1998;92:1497-1504[Abstract/Free Full Text]. 56. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619[CrossRef][Medline] [Order article via Infotrieve]. 57. Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene. 1993;8:3029-3036[Medline] [Order article via Infotrieve]. 58. Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines. Leuk Lymphoma. 2000;37:649-655[Medline] [Order article via Infotrieve]. 59. Andrews JM, Oglesbee MJ, Trevino AV, et al. Enhanced human T-cell lymphotropic virus type I expression following induction of the cellular stress response. Virology. 1995;208:816-820[CrossRef][Medline] [Order article via Infotrieve]. 60. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-B in primary adult T-cell leukemia cells. Blood. 1999;93:2360-2368[Abstract/Free Full Text]. 61. Tsukasaki K, Tomonaga M. Atra, NF-B and ATL. Leuk Res. 2001;25:407-408[CrossRef][Medline] [Order article via Infotrieve]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. K. Altman, P. Yoon, E. Katsoulidis, B. Kroczynska, A. Sassano, A. J. Redig, H. Glaser, A. Jordan, M. S. Tallman, N. Hay, et al. Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses J. Biol. Chem., January 25, 2008; 283(4): 1992 - 2001. [Abstract] [Full Text] [PDF] M. Brown, M. Bellon, and C. Nicot Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1 Blood, February 15, 2007; 109(4): 1653 - 1659. [Abstract] [Full Text] [PDF] P. Yoon, N. Giafis, J. Smith, H. Mears, E. Katsoulidis, A. Sassano, J. Altman, A. J. Redig, M. S. Tallman, and L. C. Platanias Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2815 - 2823. [Abstract] [Full Text] [PDF] P. Kannan-Thulasiraman, E. Katsoulidis, M. S. Tallman, J. S. C. Arthur, and L. C. Platanias Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide J. Biol. Chem., August 11, 2006; 281(32): 22446 - 22452. [Abstract] [Full Text] [PDF] A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence Blood, August 1, 2006; 108(3): 1021 - 1029. [Abstract] [Full Text] [PDF] N. Giafis, E. Katsoulidis, A. Sassano, M. S. Tallman, L. S. Higgins, A. R. Nebreda, R. J. Davis, and L. C. Platanias Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide-Dependent Cellular Responses. Cancer Res., July 1, 2006; 66(13): 6763 - 6771. [Abstract] [Full Text] [PDF] A. Lemarie, C. Morzadec, D. Merino, O. Micheau, O. Fardel, and L. Vernhet Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor-{kappa}B-Related Survival Pathway Down-Regulation J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 304 - 314. [Abstract] [Full Text] [PDF] S. Richardson, J. B. Budgin, J. M. Junkins-Hopkins, C. C. Vittorio, J. Lee, W. T. Miller Jr, A. H. Rook, and E. J. Kim Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1 Arch Dermatol, March 1, 2005; 141(3): 301 - 304. [Full Text] [PDF] U. Sinha-Datta, I. Horikawa, E. Michishita, A. Datta, J. C. Sigler-Nicot, M. Brown, M. Kazanji, J. C. Barrett, and C. Nicot Transcriptional activation of hTERT through the NF-{kappa}B pathway in HTLV-I-transformed cells Blood, October 15, 2004; 104(8): 2523 - 2531. [Abstract] [Full Text] [PDF] H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF] J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther., November 1, 2003; 2(11): 1155 - 1164. [Abstract] [Full Text] [PDF] R. Nasr, A. Rosenwald, M. E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de The, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells Blood, June 1, 2003; 101(11): 4576 - 4582. [Abstract] [Full Text] [PDF] T. Kanzawa, Y. Kondo, H. Ito, S. Kondo, and I. Germano Induction of Autophagic Cell Death in Malignant Glioma Cells by Arsenic Trioxide Cancer Res., May 1, 2003; 63(9): 2103 - 2108. [Abstract] [Full Text] [PDF] A. Verma, M. Mohindru, D. K. Deb, A. Sassano, S. Kambhampati, F. Ravandi, S. Minucci, D. V. Kalvakolanu, and L. C. Platanias Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide J. Biol. Chem., November 15, 2002; 277(47): 44988 - 44995. [Abstract] [Full Text] [PDF] N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii Bay 11-7082 inhibits transcription factor NF-kappa B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells Blood, August 13, 2002; 100(5): 1828 - 1834. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mahieux, R. Articles by Nicot, C. Search for Related Content PubMed PubMed Citation Articles by Mahieux, R. Articles by Nicot, C. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020